Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes. The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. Crucially, they… Read More
CureVac has announced results of the second interim analysis of its international pivotal Phase IIb/III study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV. At second interim analysis, statistical success criteria were not met. In the unprecedented context of at least 13 variants circulating… Read More
Leading research from European Journal of Lipid Science and Technology How many different types of diseases are there in the world? How will we ever be able to find cures for them? We might not be able to do so for all of them, but we may be able to… Read More
Scientific and technological advancements are making it easier to understand the causes of and physiological processes of diseases and how molecular and biochemical aspects of lipids play a role. Due to its promising application for identifying and quantifying lipids as biomarkers of disease, lipidomics research has advanced considerably in recent… Read More
Corticosteroids may be an effective treatment for children who develop a rare but serious condition after Covid-19 infection. This is the finding of an international study of 614 children, published in the New England Journal of Medicine, led by Imperial College London. All children in the study developed a serious… Read More
Sygnature Discovery has announced the set-up of an Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving the way for clinical trials. With over £1 million… Read More
Aly King-Smith is Director of Clearworks, based at the historic Caswell Science Park in Northamptonshire. King-Smith speaks with DDW’s Megan Thomas about Clearworks’ Lab To Leadership initiative, established to inspire leaders in STEM. MT: Could you provide a general overview of the course and the company behind it? AKS: Lab… Read More
In the latest sponsored DDW podcast, discover how accurate and quantitative analysis of product purity is a fundamental for effective development of biotherapeutic proteins. This episode features DDW Editor in Chief Lu Rahman and Tufan Aydogdu, Field Applications Manager of ProteinSimple, a Bio-Techne brand. Aydogdu talks Lu through how the… Read More
The latest DDW Sponsored Sitting Down With podcast features Tufan Aydogdu, Field Applications Manager, ProteinSimple, a Bio-Techne brand. Dr. Aydogdu talks us through how the accurate and quantitative analysis of product purity is a fundamental component of effective development of a biotherapeutic protein. But without consistent techniques and high-quality,… Read More
Genetic Analysis (GA) has announced that the Norwegian Research Council has approved its grant application of NOK 16 million (€1.6 million) for its project developing new innovative microbiome-based diagnostics to be used to aid selection and treatment of Inflammatory Bowel Disease (IBD) patients. In this project, GA will develop an… Read More
New data from Public Health England (PHE) demonstrated AstraZeneca’s Covid-19 vaccine offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant). Real world data from PHE, published as a pre-print, demonstrated two doses of AstraZeneca are 92% effective against hospitalisation due to the Delta variant and… Read More
Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More
Domainex has been awarded ‘Best CRO’ at the OBN Awards 2020. Dr Tom Mander, CEO, Dr Ray Boffey, Executive Director of Medicines Research, and Dr Cat Stace, Director of Business Development, attended the postponed awards ceremony in London on June 11, 2021. Domainex has invested in new technology to support… Read More
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs). Starting in June 2021, Evonik and Stanford scientists begin a three-year sponsored research collaboration to develop the polymer-based drug delivery system, which Evonik will license… Read More
Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward… Read More
Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward… Read More
